Announcement of the National Medical Products Administration, the Ministry of Public Security, and the National Health Commission, on the Inclusion of Varieties including Oxycodone-containing Medicines as Psychotropic Drugs

　　No. 63 of 2019

　　In accordance with the relevant provisions of the Regulations on the Control of Narcotic Drugs and Psychotropic Drugs, the National Medical Products Administration, the Ministry of Public Security, and the National Health Commission have decided to regulate varieties including oxycodone-containing medicines as psychotropic drugs.

　　It is hereby announced as follows:

　　1. Solid oral medicines which contain more than 5 mg of oxycodone base per dosage unit and contain no other narcotic drugs, psychotropic drugs or pharmaceutical precursor chemicals shall be included in CategoryⅠof the psychotropic drugs.

　　2. Solid oral medicines which contain no more than 5 mg of oxycodone base per dosage unit and contain no other narcotic drugs, psychotropic drugs or pharmaceutical precursor chemicals shall be included in Category Ⅱ of the psychotropic drugs.

　　3. Solid oral medicines which contain buprenorphine and naloxone shall be included in Category Ⅱ of the psychotropic drugs.

　　This announcement shall come into effect as of September 1, 2019.